Are uric acid levels different from healthy subjects in bipolar affective disorder and schizophrenia?: Relationship between clinical improvement and episode severity in male patients;Ürik asit düzeyleri İki uçlu bozukluk ve şizofrenide sağlıklı bireylerden farklı mıdır?: Erkek cinsiyette klinik İyileşme ve dönem şiddeti ile İlişkisi

Noropsikiyatri Arsivi

Volumn 51, Issue 3, 2014, Pages 229-232

  Gültekİn, Bülent Kadri ^a   Kesebİr, Sermin ^a   Kabak, Sevgi Gül ^a   Ergün, Ferzan Fikret ^a   Tatlidİl Yaylaci, Elif ^a  

^a stanbul Erenköy Ruh ve Sinir Hastal klar E itim ve Ara t rma Hastanesi   (Turkey)

Author keywords

Bipolar disorder; Schizophrenia; Uric acid

Indexed keywords

URIC ACID;

ARTICLE; BIPOLAR DISORDER; BIPOLAR MANIA; CONTROLLED STUDY; DISEASE SEVERITY; GENERAL CONDITION IMPROVEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; RELAPSE; SCHIZOPHRENIA; URIC ACID BLOOD LEVEL; YOUNG MANIA RATING SCALE;

EID: 84907855344     PISSN: 13000667     EISSN: None     Source Type: Journal    
DOI: 10.4274/npa.y6827     Document Type: Article

References (23)

1. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 2008; 7: 575-590.
2. Jinnah HA. Lesch-Nyhan disease: from mechanism to model and back again. Dis Model Mech 2009; 2: 116-121.
3. Lorenzi TM, Borba DL, Dutra G, Lara DR. Association of serum uric acid levels with emotional and affective temperaments. J Affect Disord 2009; 121: 161-164.
4. Zarate CA Jr, Manji HK. Bipolar disorder: candidate drug targets. Mt Sinai J Med 2008; 75: 226-247.
5. McQuillin A, Bass NJ, Choudry K, Puri V, Kosmin M, Lawrence J, Curtis D, Gurling HM. Case-control studies show that a non-conservative aminoacid change from a glutamine to arginine in the P2RX7 purinergic receptor protein is associated with both bipolar- and unipolar-affective disorders. Mol Psychiatry 2009; 14: 614-620.
6. Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G, Cunha A, Souza DO, Zarate CAJr, Kapczinski F. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008; 69: 1237-1245.
7. Salvadore G, Viale CI, Luckenbaugh DA, Zanatto VC, Portela LV, Souza DO, Zarate CA Jr, Machado-Vieira R. Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 819-821.
8. Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 1998; 80: 29-39.
9. Yao JK, Reddy R, van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000; 97: 137-151.
10. Reddy RD, Keshavan MS, Yao JK. Reduced plasma antioxidants in first episode patients with schizophrenia. Schizophr Res 2003; 62: 205-212.
11. Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 2010; 15: 938-953.
12. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV clinical version (SCID-I/CV). Washington: American Psychiatric Press; 1997.
13. Özkürkçügil A, Aydemir Ö, Yıldız M. DSM-IV Eksen I Bozuklukları İçin Yapılandırılmış Klinik Görüşmenin Türkçe'ye Uyarlanması ve Güvenilirlik Çalışması. İlaç ve Tedavi Dergisi 1999; 12: 233-236.
14. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scala for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978; 133: 429-435.
15. Karadag F, Oral ET, Yalçın FA, Erten E. Young Mani Derecelendirme Ölçeginin Türkiye' de geçerlik ve güvenirligi. Turk Psikiyatri Dergisi 2001; 13: 107-114.
16. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-275.
17. Kostakoğlu AE, Batur S, Tiryaki A. Pozitif ve negatif sendrom ölçeğinin (PANSS) Türkçe uyarlamasının geçerlilik ve güvenilirliği. Türk Psikoloji Dergisi 1999; 14: 23-32.
18. Machado-Vieira R, Lara DR, Souza DO, Kapczinski F. Purinergic dysfunction in mania: an integrative model. Med Hypotheses 2002; 58: 297-304.
19. Anumonye A, Reading HW, Knight F, Ashcroft GW. Uric-acid metabolism in manicdepressive illness and during lithium therapy. Lancet 1968; 1: 1290-1293.
20. Ring HA, Heller AJ, Marshall WJ, Johnson AL, Reynolds EH. Plasma uric acid levels in patients receiving anticonvulsant monotherapy. Epilepsy Res 1991; 8: 241-244.
21. Brooks SC, LinnJJ, Disney N. Serotonin, folic acid, and uric acid metabolism in the diagnosis of neuropsychiatric disorders. Biol Psychiatry 1978; 13: 671-684.
22. Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R. Homeostatic imbalance of purine catabolism in firstepisode neuroleptic-naive patients with schizophrenia. PLoS One 2010; 5: e9508.
23. Bloch M, Gur E, Shalev AY. Hypouricemic effect of zuclopenthixol: a potential Marker of drug compliance? Psychopharmacology (Berl) 1992; 109: 377-378.